Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Immunologic Research
Erschienen in: Immunologic Research 2/2023

21.10.2022 | Review

Macrophage subsets and their role: co-relation with colony-stimulating factor-1 receptor and clinical relevance

verfasst von: Shivani Yadav, Astik Priya, Diksha R. Borade, Reena Agrawal-Rajput

Erschienen in: Immunologic Research | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Macrophages are one of the first innate immune cells to reach the site of infection or injury. Diverse functions from the uptake of pathogen or antigen, its killing, and presentation, the release of pro- or anti-inflammatory cytokines, activation of adaptive immune cells, clearing off tissue debris, tissue repair, and maintenance of tissue homeostasis have been attributed to macrophages. Besides tissue-resident macrophages, the circulating macrophages are recruited to different tissues to get activated. These are highly plastic cells, showing a spectrum of phenotypes depending on the stimulus received from their immediate environment. The macrophage differentiation requires colony-stimulating factor-1 (CSF-1) or macrophage colony-stimulating factor (M-CSF), colony-stimulating factor-2 (CSF-2), or granulocyte–macrophage colony-stimulating factor (GM-CSF) and different stimuli activate them to different phenotypes. The richness of tissue macrophages is precisely controlled via the CSF-1 and CSF-1R axis. In this review, we have given an overview of macrophage origin via hematopoiesis/myelopoiesis, different phenotypes associated with macrophages, their clinical significance, and how they are altered in various diseases. We have specifically focused on the function of CSF-1/CSF-1R signaling in deciding macrophage fate and the outcome of aberrant CSF-1R signaling in relation to macrophage phenotype in different diseases. We further extend the review to briefly discuss the possible strategies to manipulate CSF-1R and its signaling with the recent updates.

Graphical Abstract

Literatur
1.
Mertens, C. et al. The macrophage iron signature in health and disease. Int. J. Mol. Sci. 22, (2021).
2.
Hirayama, D., Iida, T. & Nakase, H. The Phagocytic function of macrophage-enforcing innate immunity and tissue homeostasis. Int. J. Mol. Sci. 19, (2017).
3.
4.
Italiani, P. & Boraschi, D. From monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation. Frontiers in Immunology vol. 5 (2014).
5.
Benoit M, Desnues B, Mege J-L. Macrophage polarization in bacterial infections. J Immunol. 2008;181:3733–9.PubMedCrossRef
6.
7.
8.
Mosser DM, Hamidzadeh K, Goncalves R. Macrophages and the maintenance of homeostasis. Cell Mol Immunol. 2021;18:579–87.PubMedCrossRef
9.
Wang WY, Tan MS, Yu JT, Tan L. Role of pro-inflammatory cytokines released from microglia in Alzheimer’s disease. Ann Transl Med. 2015;3:7–7.
10.
Shah, D. et al. Berberine mediates tumor cell death by skewing tumor-associated immunosuppressive macrophages to inflammatory macrophages. Phytomedicine 99, (2021).
11.
Moreira AP, et al. Serum amyloid P attenuates M2 macrophage activation and protects against fungal spore–induced allergic airway disease. J Allergy Clin Immunol. 2010;126:712-721.e7.PubMedCrossRef
12.
A-Gonzalez, N. et al. Phagocytosis imprints heterogeneity in tissue-resident macrophages. J. Exp. Med. 214, 1281–1296 (2017).
13.
Zhang B, et al. Azithromycin drives alternative macrophage activation and improves recovery and tissue sparing in contusion spinal cord injury. J Neuroinflammation. 2015;12:1–13.CrossRef
14.
15.
16.
Arroyo Portilla, C., Tomas, J., Gorvel, J. P. & Lelouard, H. From species to regional and local specialization of intestinal macrophages. Front. Cell Dev. Biol. 8, (2020).
17.
Gold KS, Brückner K. Macrophages and cellular immunity in Drosophila melanogaster. Semin Immunol. 2015;27:357.PubMedCrossRef
18.
Cavaillon J-M. The historical milestones in the understanding of leukocyte biology initiated by Elie Metchnikoff. J Leukoc Biol. 2011;90:413–24.PubMedCrossRef
19.
20.
21.
Gaikwad S, Naveen C, Agrawal-Rajput R. Toll-like receptor-4 antagonism mediates benefits during neuroinflammation. Neural Regen Res. 2016;11:552–3.PubMedPubMedCentralCrossRef
22.
23.
Hoggatt J, Kfoury Y, Scadden DT. Hematopoietic stem cell niche in health and disease. Annu Rev Pathol. 2016;11:555–81.PubMedCrossRef
24.
Mak, K. S., Funnell, A. P. W., Pearson, R. C. M. & Crossley, M. PU.1 and haematopoietic cell fate: dosage matters. Int. J. Cell Biol. 2011, (2011).
25.
Qiu Q, et al. IRF8 regulates cell cycle of hematopoietic stem cells. Blood. 2015;126:2353–2353.CrossRef
26.
27.
28.
M, M. et al. Numerous growth factors, cytokines, and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood 97, 3075–3085 (2001).
29.
Stegelmeier, A. A. et al. Myeloid cells during viral infections and inflammation. Viruses vol. 11 (2019).
30.
31.
Yang J, Zhang L, Yu C, Yang XF, Wang H. Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases. Biomark Res. 2014;2:1.PubMedPubMedCentralCrossRef
32.
33.
Schultze JL, Mass E, Schlitzer A. Emerging principles in myelopoiesis at homeostasis and during infection and inflammation. Immunity. 2019;50:288–301.PubMedCrossRef
34.
Boettcher S, Manz MG. Regulation of inflammation- and infection-driven hematopoiesis. Trends Immunol. 2017;38:345–57.PubMedCrossRef
35.
Furusawa, J. I. et al. Promotion of expansion and differentiation of hematopoietic stem cells by interleukin-27 into myeloid progenitors to control infection in emergency myelopoiesis. PLoS Pathog. 12, (2016).
36.
Kumar R, Fossati V, Israel M, Snoeck H-W. Lin-Sca1+Kit- bone marrow cells contain early lymphoid-committed precursors that are distinct from common lymphoid progenitors. J Immunol. 2008;181:7507.PubMedCrossRef
37.
Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 2008;13:453–61.PubMedCrossRef
38.
Heideveld E, et al. Methods for macrophage differentiation and in vitro generation of human tumor associated-like macrophages. Methods Enzymol. 2020;632:113–31.PubMedCrossRef
39.
40.
Orecchioni, M., Ghosheh, Y., Pramod, A. B. & Ley, K. Macrophage polarization: different gene signatures in M1(Lps+) vs. classically and M2(LPS-) vs. alternatively activated macrophages. Front. Immunol. 10, 1084 (2019).
41.
Zhang F, et al. TGF-β induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype. Oncotarget. 2016;7:52294.PubMedPubMedCentralCrossRef
42.
Makita N, Hizukuri Y, Yamashiro K, Murakawa M, Hayashi Y. IL-10 enhances the phenotype of M2 macrophages induced by IL-4 and confers the ability to increase eosinophil migration. Int Immunol. 2015;27:131–41.PubMedCrossRef
43.
Melton DW, McManus LM, Gelfond JAL, Shireman PK. Temporal phenotypic features distinguish polarized macrophages in vitro. Autoimmunity. 2015;48:161–76.PubMedPubMedCentralCrossRef
44.
Zhang M-Z, et al. IL-4/IL-13-mediated polarization of renal macrophages/dendritic cells to an M2a phenotype is essential for recovery from acute kidney injury. Kidney Int. 2017;91:375–86.PubMedCrossRef
45.
Rogers KJ, et al. IL-4/IL-13 polarization of macrophages enhances Ebola virus glycoprotein-dependent infection. PLoS Negl Trop Dis. 2019;13: e0007819.PubMedPubMedCentralCrossRef
46.
Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol. 2011;30:16–34.PubMedCrossRef
47.
48.
49.
Challagundla N, Shah D, Yadav S, Agrawal-Rajput R. Saga of monokines in shaping tumour-immune microenvironment: origin to execution. Cytokine. 2022;157: 155948.PubMedCrossRef
50.
51.
Corliss BA, Azimi MS, Munson JM, Peirce SM, Murfee WL. Macrophages: an inflammatory link between angiogenesis and lymphangiogenesis. Microcirculation. 2016;23:95.PubMedPubMedCentralCrossRef
52.
Medvedeva GF, Kuzmina DO, Nuzhina J, Shtil AA, Dukhinova MS. How macrophages become transcriptionally dysregulated: a hidden impact of antitumor therapy. Int J Mol Sci. 2021;22:1–27.CrossRef
53.
Schliefsteiner, C. et al. Human placental Hofbauer cells maintain an anti-inflammatory m2 phenotype despite the presence of gestational diabetes mellitus . Frontiers in Immunology vol. 8 (2017).
54.
Raggi F, et al. Regulation of human macrophage M1–M2 polarization balance by hypoxia and the triggering receptor expressed on myeloid cells-1. Front Immunol. 2017;8:1–18.CrossRef
55.
56.
Lu J, et al. Discrete functions of M2a and M2c macrophage subsets determine their relative efficacy in treating chronic kidney disease. Kidney Int. 2013;84:745–55.PubMedCrossRef
57.
Rhee I. Diverse macrophages polarization in tumor microenvironment. Arch Pharm Res. 2016;39:1588–96.PubMedCrossRef
58.
Wang, L. xun, Zhang, S. xi, Wu, H. juan, Rong, X. lu & Guo, J. M2b macrophage polarization and its roles in diseases. J. Leukoc. Biol. 106, 345 (2019).
59.
Wang, Q. et al. Fra-1 protooncogene regulates IL-6 expression in macrophages and promotes the generation of M2d macrophages. Cell Res. 2010 206 20, 701–712 (2010).
60.
Mills CD. M1 and M2 macrophages: oracles of health and disease. Crit Rev Immunol. 2012;32:463–88.PubMedCrossRef
61.
Atri, C., Guerfali, F. Z. & Laouini, D. Role of human macrophage polarization in inflammation during infectious diseases. Int. J. Mol. Sci. 19, (2018).
62.
Kazankov K, et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol. 2019;16:145–59.PubMedCrossRef
63.
Medbury, H. J., Williams, H. & Fletcher, J. P. Clinical significance of macrophage phenotypes in cardiovascular disease. Clin. Transl. Med. 3, (2014).
64.
Huang, J., Hou, F. L., Zhang, A. Y. & Li, Z. L. Protective effect of the polarity of macrophages regulated by IL-37 on atherosclerosis. Genet. Mol. Res. 15, (2016).
65.
Ardura-Fabregat, A. et al. Targeting neuroinflammation to treat Alzheimer’s disease. CNS Drugs 2017 3112 31, 1057–1082 (2017).
66.
Zhang, Q. wen et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One 7, e50946 (2012).
67.
Gobejishvili, L. et al. Chronic ethanol-mediated decrease in cAMP primes macrophages to enhanced LPS-inducible NF-kappaB activity and TNF expression: relevance to alcoholic liver disease. Am. J. Physiol. Gastrointest. Liver Physiol. 291, (2006).
68.
McClain CJ, Cohen DA. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology. 1989;9:349–51.PubMedCrossRef
69.
70.
Yu S, Ge H, Li S, Qiu HJ. Modulation of macrophage polarization by viruses: turning off/on host antiviral responses. Front Microbiol. 2022;13:130.
71.
72.
73.
Jimenez MDP, Walls L, Fierer J. High levels of interleukin-10 impair resistance to pulmonary coccidioidomycosis in mice in part through control of nitric oxide synthase 2 expression. Infect Immun. 2006;74:3387–95.PubMedPubMedCentralCrossRef
74.
Cosma NC, et al. M1/M2 polarization in major depressive disorder: disentangling state from trait effects in an individualized cell-culture-based approach. Brain Behav Immun. 2021;94:185–95.PubMedCrossRef
75.
76.
Velazquez-Salinas L, Verdugo-Rodriguez A, Rodriguez LL, Borca MV. The role of interleukin 6 during viral infections. Front Microbiol. 2019;10:1057.PubMedPubMedCentralCrossRef
77.
Komastu T, Ireland DDC, Reiss CS. IL-12 and viral infections. Cytokine Growth Factor Rev. 1998;9:277.PubMedCrossRef
78.
Mattiola I, et al. Priming of human resting NK cells by autologous m1 macrophages via the engagement of IL-1β, IFN-β, and IL-15 pathways. J Immunol. 2015;195:2818–28.PubMedCrossRef
79.
Sahoo M, Ceballos-Olvera I, Del Barrio L, Re F. Role of the inflammasome, IL-1β, and IL-18 in bacterial infections. Sci World J. 2011;11:2037.CrossRef
80.
Ouyang P, et al. IL-10 encoded by viruses: a remarkable example of independent acquisition of a cellular gene by viruses and its subsequent evolution in the viral genome. J Gen Virol. 2014;95:245–62.PubMedCrossRef
81.
82.
Kwon YC, et al. Hepatitis C virus E2 envelope glycoprotein induces an immunoregulatory phenotype in macrophages. Hepatology. 2019;69:1873.PubMedCrossRef
83.
Granja AG, Sabina P, Salas ML, Fresno M, Revilla Y. Regulation of inducible nitric oxide synthase expression by viral A238L-mediated inhibition of p65/RelA acetylation and p300 transactivation. J Virol. 2006;80:10487–96.PubMedPubMedCentralCrossRef
84.
Cameron CM, Barrett JW, Liu L, Lucas AR, McFadden G. Myxoma virus M141R expresses a viral CD200 (vOX-2) that is responsible for down-regulation of macrophage and T-cell activation in vivo. J Virol. 2005;79:6052–67.PubMedPubMedCentralCrossRef
85.
Cameron CM, Barrett JW, Mann M, Lucas A, McFadden G. Myxoma virus M128L is expressed as a cell surface CD47-like virulence factor that contributes to the downregulation of macrophage activation in vivo. Virology. 2005;337:55–67.PubMedCrossRef
86.
Reichard AC, Cheemarla NR, Bigley NJ. SOCS1/3 expression levels in HSV-1-Infected, cytokine-polarized and -unpolarized macrophages. J Interf Cytokine Res. 2015;35:32.CrossRef
87.
Yokota SI, et al. Herpes simplex virus type 1 suppresses the interferon signaling pathway by inhibiting phosphorylation of STATs and janus kinases during an early infection stage. Virology. 2001;286:119–24.PubMedCrossRef
88.
Stumptner-Cuvelette P, et al. Human immunodeficiency virus-1 nef expression induces intracellular accumulation of multivesicular bodies and major histocompatibility complex Class II complexes: potential role of phosphatidylinositol 3-kinase. Mol Biol Cell. 2003;14:4857.PubMedPubMedCentralCrossRef
89.
Rogers KJ, et al. IL-4/IL-13 polarization of macrophages enhances Ebola virus glycoprotein-dependent infection. PLoS Negl Trop Dis. 2019;13: e0007819.PubMedPubMedCentralCrossRef
90.
Miller BH, et al. Mycobacteria inhibit nitric oxide synthase recruitment to phagosomes during macrophage infection. Infect Immun. 2004;72:2872–8.PubMedPubMedCentralCrossRef
91.
Biswas T. Role of porin of Shigella dysenteriae type 1 in modulation of lipopolysaccharide mediated nitric oxide and interleukin-1 release by murine peritoneal macrophages. FEMS Immunol Med Microbiol. 2000;29:129–36.PubMedCrossRef
92.
93.
Zhang J, et al. NLRP3 inflammasome mediates M1 macrophage polarization and IL-1β production in inflammatory root resorption. J Clin Periodontol. 2020;47:451–60.PubMedCrossRef
94.
95.
Suzuki T, et al. Differential regulation of caspase-1 activation, pyroptosis, and autophagy via Ipaf and ASC in Shigella-infected macrophages. PLoS Pathog. 2007;3:1082–91.CrossRef
96.
Cooper AM, Magram J, Ferrante J, Orme IM. Interleukin 12 (IL-12) Is crucial to the development of protective immunity in mice intravenously infected with mycobacterium tuberculosis. J Exp Med. 1997;186:39–45.PubMedPubMedCentralCrossRef
97.
Huang, Z. et al. Mycobacterium tuberculosis-induced polarization of human macrophage orchestrates the formation and development of tuberculous granulomas in vitro. PLoS One 10, (2015).
98.
99.
Gustot T. Multiple organ failure in sepsis: prognosis and role of systemic inflammatory response. Curr Opin Crit Care. 2011;17:153–9.PubMedCrossRef
100.
Chaudhry, H. et al. Role of cytokines as a double-edged sword in sepsis. in Vivo 27, 669 (2013).
101.
102.
Challagundla, N., Shah, D., Yadav, S. & Agrawal-rajput, R. CO.
103.
104.
Cassetta L, Cassol E, Poli G. Macrophage polarization in health and disease. Sci World J. 2011;11:2391.CrossRef
105.
Corthay A, et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity. 2005;22:371–83.PubMedCrossRef
106.
Liu Y, Cao X. The origin and function of tumor-associated macrophages. Cell Mol Immunol. 2015;12:1.PubMedCrossRef
107.
Gamrekelashvili J, et al. Notch and TLR signaling coordinate monocyte cell fate and inflammation. Elife. 2020;9:1–19.CrossRef
108.
Kong, D. H., Kim, Y. K., Kim, M. R., Jang, J. H. & Lee, S. Emerging roles of vascular cell adhesion molecule-1 (VCAM-1) in immunological disorders and cancer. Int. J. Mol. Sci. 19, (2018).
109.
Kitamura, T. et al. Monocytes differentiate to immune suppressive precursors of metastasis-associated macrophages in mouse models of metastatic breast cancer. Front. Immunol. 8, (2018).
110.
He, Z. & Zhang, S. Tumor-associated macrophages and their functional transformation in the hypoxic tumor microenvironment. Front. Immunol. 12, (2021).
111.
Landry, A. P., Balas, M., Alli, S., Spears, J. & Zador, Z. Distinct regional ontogeny and activation of tumor associated macrophages in human glioblastoma. Sci. Rep. 10, (2020).
112.
Wang, H., Tian, T. & Zhang, J. Tumor-Associated Macrophages (TAMs) in Colorectal Cancer (CRC): from mechanism to therapy and prognosis. Int. J. Mol. Sci. 22, (2021).
113.
Krockenberger M, et al. Macrophage migration inhibitory factor (MIF) contributes to the immune escape of ovarian cancer by downregulating NKG2D. J Immunol. 2008;180:7338.PubMedCrossRef
114.
Onodera S, et al. Macrophage migration inhibitory factor induces phagocytosis of foreign particles by macrophages in autocrine and paracrine fashion. Immunology. 1997;92:131–7.PubMedPubMedCentralCrossRef
115.
Pozzi LAM, Weiser WY. Human recombinant migration inhibitory factor activates human macrophages to kill tumor cells. Cell Immunol. 1992;145:372–9.PubMedCrossRef
116.
Mao C, Ding Y, Xu N. A double-edged sword role of cytokines in prostate cancer immunotherapy. Front Oncol. 2021;11:4732.CrossRef
117.
Di Caro G, et al. Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Gut. 2016;65:1710–20.PubMedCrossRef
118.
Rhee I. Diverse macrophages polarization in tumor microenvironment. Arch Pharm Res. 2016;39:1588–96.PubMedCrossRef
119.
Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev. 2006;25:435–57.PubMedCrossRef
120.
Erreni M, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) and inflammation in colorectal cancer. Cancer Microenviron. 2011;4:141–54.PubMedCrossRef
121.
Di Caro G, et al. Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Gut. 2015;65:1710–20.PubMedCrossRef
122.
Liu, K. X. & Joshi, S. “Re-educating” tumor associated macrophages as a novel immunotherapy strategy for neuroblastoma. Front. Immunol. 11, (2020).
123.
Gomez-Roca C, et al. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade. J Immunother Cancer. 2022;10: e004076.PubMedPubMedCentralCrossRef
124.
Thangam EB, et al. The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: the hunt for new therapeutic targets. Front Immunol. 2018;9:1873.PubMedPubMedCentralCrossRef
125.
Nakano K, Takamatsu S. Histamine produced by macrophage and T lymphocyte: a new type of signal transducer. Nihon Yakurigaku Zasshi. 2001;118:15–22.PubMedCrossRef
126.
Suzuki K, Meguro K, Nakagomi D, Nakajima H. Roles of alternatively activated M2 macrophages in allergic contact dermatitis. Allergol Int. 2017;66:392–7.PubMedCrossRef
127.
Saradna A, Do DC, Kumar S, Fu QL, Gao P. Macrophage polarization and allergic asthma. Transl Res. 2018;191:1.PubMedCrossRef
128.
Iwasaki N, et al. Th2 cells and macrophages cooperatively induce allergic inflammation through histamine signaling. PLoS ONE. 2021;16:1–18.CrossRef
129.
Draijer, C., Robbe, P., Boorsma, C. E., Hylkema, M. N. & Melgert, B. N. Dual role of YM1+ M2 macrophages in allergic lung inflammation. Sci. Reports 2018 81 8, 1–12 (2018).
130.
Day DL, Chakari W, Matzen SH. Malignant transformation of a non-healing traumatic wound on the lower extremity: A case report. Int J Surg Case Rep. 2018;53:468–70.PubMedPubMedCentralCrossRef
131.
132.
Watanabe S, Alexander M, Misharin AV, Budinger GRS. The role of macrophages in the resolution of inflammation. J Clin Invest. 2019;129:2619–28.PubMedPubMedCentralCrossRef
133.
134.
Kang K, et al. Interferon-γ represses M2 gene expression in human macrophages by disassembling enhancers bound by the transcription factor MAF. Immunity. 2017;47:235.PubMedPubMedCentralCrossRef
135.
136.
Achkova D, Maher J. Role of the colony-stimulating factor (CSF)/CSF-1 receptor axis in cancer. Biochem Soc Trans. 2016;44:333–41.PubMedCrossRef
137.
138.
Sinha SK, et al. HHS Public Access. 2022;41:220–33.
139.
140.
Ryan GR, et al. Rescue of the colony-stimulating factor 1 (CSF-1)-nullizygous mouse (Csf1op/Csf1op) phenotype with a CSF-1 transgene and identification of sites of local CSF-1 synthesis. Blood. 2001;98:74–84.PubMedCrossRef
141.
142.
Horiuchi K, et al. Cell surface colony-stimulating factor 1 can be cleaved by tnf-α converting enzyme or endocytosed in a clathrin-dependent manner. J Immunol. 2007;179:6715–24.PubMedCrossRef
143.
144.
Hume DA, MacDonald KPA. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood. 2012;119:1810–20.PubMedCrossRef
145.
146.
147.
Felix J, et al. Structure and assembly mechanism of the signaling complex mediated by human CSF-1. Structure. 2015;23:1621–31.PubMedCrossRef
148.
Wei 10_Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1.pdf.
149.
Liu H, et al. The mechanism of shared but distinct CSF-1R signaling by the non-homologous cytokines IL-34 and CSF-1. Biochim Biophys Acta - Proteins Proteomics. 2012;1824:938–45.CrossRef
150.
Stanley, E. R. & Chitu, V. CSF-1 receptor signaling in myeloid cells. Cold Spring Harb. Perspect. Biol. 6, (2014).
151.
Seita J, Weissman IL. Published in final edited form as: Hematopoietic stem cell: self-renewal versus differentiation. Wiley Interdiscip Rev Syst Biol Med. 2010;2:1–20.CrossRef
152.
Lee AWM, States DJ. Colony-stimulating factor-1 requires PI3-kinase-mediated metabolism for proliferation and survival in myeloid cells. Cell Death Differ. 2006;13:1900–14.PubMedCrossRef
153.
Vergadi E, Ieronymaki E, Lyroni K, Vaporidi K, Tsatsanis C. Akt signaling pathway in macrophage activation and M1/M2 polarization. J Immunol. 2017;198:1006–14.PubMedCrossRef
154.
Caescu CI, et al. Colony stimulating factor-1 receptor signaling networks inhibit mouse macrophage inflammatory responses by induction of microRNA-21. Blood. 2015;125:e1–13.PubMedPubMedCentralCrossRef
155.
Feng J, et al. MiR-21 attenuates lipopolysaccharide-induced lipid accumulation and inflammatory response: Potential role in cerebrovascular disease. Lipids Health Dis. 2014;13:1–9.CrossRef
156.
He H, et al. Endothelial cells provide an instructive niche for the differentiation and functional polarization of M2-like macrophages. Blood. 2012;120:3152–62.PubMedPubMedCentralCrossRef
157.
Hamilton TA, Zhao C, Pavicic PG, Datta S. Myeloid colony-stimulating factors as regulators of macrophage polarization. Front Immunol. 2014;5:1–6.CrossRef
158.
J Leukocyte Bio - 2009 - Fleetwood - GM‐CSF‐ and M‐CSF‐dependent macrophage phenotypes display differential dependence on.pdf.
159.
Mia S, Warnecke A, Zhang XM, Malmström V, Harris RA. An optimized protocol for human M2 macrophages using M-CSF and IL-4/IL-10/TGF-β yields a dominant immunosuppressive phenotype. Scand J Immunol. 2014;79:305–14.PubMedPubMedCentralCrossRef
160.
Osman A, et al. M-CSF inhibits anti–HIV-1 activity of IL-32, but they enhance M2-like phenotypes of macrophages. J Immunol. 2014;192:5083–9.PubMedCrossRef
161.
Erblich, B., Zhu, L., Etgen, A. M., Dobrenis, K. & Pollard, J. W. Absence of colony stimulation factor-1 receptor results in loss of microglia, disrupted brain development and olfactory deficits. PLoS One 6, (2011).
162.
Rojo R, et al. Deletion of a Csf1r enhancer selectively impacts CSF1R expression and development of tissue macrophage populations. Nat Commun. 2019;10:1–17.CrossRef
163.
Cannarile MA, et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer. 2017;5:1–13.CrossRef
164.
Journal Orthopaedic Research - 2008 - Sarahrudi - The impact of colony‐stimulating factor‐1 on fracture healing An.pdf.
165.
Takei I, et al. High macrophage-colony stimulating factor levels in synovial fluid of loose artificial hip joints. J Rheumatol. 2000;27:894–9.PubMed
166.
Klebl FH, Olsen JE, Jain S, Doe WF. Expression of macrophage-colony stimulating factor in normal and inflammatory bowel disease intestine. J Pathol. 2001;195:609–15.PubMedCrossRef
167.
Isbel, N. M., Nikolic-Paterson, D. J., Hill, P. A., Dowling, J. & Atkins, R. C. Local macrophage proliferation correlates with increased renal M-CSF expression in human glomerulonephritis. Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc. 16, 1638–1647 (2001).
168.
Jose MD, Le Meur Y, Atkins RC, Chadban SJ. Blockade of macrophage colony-stimulating factor reduces macrophage proliferation and accumulation in renal allograft rejection. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2003;3:294–300.CrossRef
169.
Rosenfeld ME, et al. Macrophage colony-stimulating factor mRNA and protein in atherosclerotic lesions of rabbits and humans. Am J Pathol. 1992;140:291–300.PubMedPubMedCentral
170.
Lin, E. Y., Nguyen, A. V, Russell, R. G. & Pollard, J. W. Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy. J. Exp. Med. 193, 727–740 (2001).
171.
Beirão BCB, et al. A blocking antibody against canine CSF-1R maturated by limited CDR mutagenesis. Antib Ther. 2020;3:193–204.PubMedPubMedCentral
172.
Aharinejad S, et al. Colony-Stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res. 2004;64:5378–84.PubMedCrossRef
173.
Strachan DC, et al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells. Oncoimmunology. 2013;2:1–12.CrossRef
174.
Lee K-H, et al. Discovery of BPR1R024, an orally active and selective CSF1R inhibitor that exhibits antitumor and immunomodulatory activity in a murine colon tumor model. J Med Chem. 2021;64:14477–97.PubMedCrossRef
175.
Bo L, Bo X. Colony stimulating factor 1: friend or foe of neurons? Neural Regen Res. 2022;17:773–4.PubMedCrossRef
176.
Orihuela R, McPherson CA, Harry GJ. Microglial M1/M2 polarization and metabolic states. Br J Pharmacol. 2016;173:649–65.PubMedCrossRef
177.
Xu Y, Jin M-Z, Yang Z-Y, Jin W-L. Microglia in neurodegenerative diseases. Neural Regen Res. 2021;16:270–80.PubMedCrossRef
178.
Wyatt-Johnson SK, Sommer AL, Shim KY, Brewster AL. Suppression of microgliosis with the colony-stimulating factor 1 receptor inhibitor PLX3397 does not attenuate memory defects during epileptogenesis in the rat. Front Neurol. 2021;12: 651096.PubMedPubMedCentralCrossRef
179.
Hu, X. et al. Rh-CSF1 Attenuates oxidative stress and neuronal apoptosis via the CSF1R/PLCG2/PKA/UCP2 signaling pathway in a rat model of neonatal HIE. Oxid. Med. Cell. Longev. 2020, (2020).
180.
Wlodarczyk A, et al. CSF1R stimulation promotes increased neuroprotection by CD11c+ microglia in EAE. Front Cell Neurosci. 2019;12:1–10.CrossRef
181.
Luo J, et al. Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival. J Exp Med. 2013;210:157–72.PubMedPubMedCentralCrossRef
182.
Huang, L., Xu, X. & Hao, Y. The possible mechanisms of tumor progression via CSF-1/CSF-1R pathway activation. Rom. J. Morphol. Embryol. = Rev. Roum. Morphol. Embryol. 55, 501–506 (2014).
183.
Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160:48–61.PubMedPubMedCentralCrossRef
184.
Holmgaard RB, et al. Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy. Oncoimmunology. 2016;5:e1151595–e1151595.PubMedPubMedCentralCrossRef
185.
Kowal J, Kornete M, Joyce JA. Re-education of macrophages as a therapeutic strategy in cancer. Immunotherapy. 2019;11:677–89.PubMedCrossRef
186.
Woo H-H, Chambers SK. The alternative spliced 3’-UTR mediated differential secretion of macrophage colony stimulating factor in breast cancer cells. Biochem Biophys Res Commun. 2020;525:1004–10.PubMedCrossRef
187.
Han J, et al. Inhibition of colony stimulating factor-1 receptor (CSF-1R) as a potential therapeutic strategy for neurodegenerative diseases: opportunities and challenges. Cell Mol Life Sci. 2022;79:219.PubMedPubMedCentralCrossRef
188.
MacDonald KPA, et al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood. 2010;116:3955–63.PubMedCrossRef
189.
Conway JG, et al. Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats. J Pharmacol Exp Ther. 2008;326:41–50.PubMedCrossRef
190.
Toh, M.-L. et al. A CSF-1 receptor monoclonal antibody has potent bone and cartilage protective effects in experimental arthritis. Arthritis Rheumatol. 66, (2014).
191.
Koyama K, et al. Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice. Mod Rheumatol. 2007;17:306–10.PubMedCrossRef
192.
Wang X-F, et al. Colony-stimulating factor 1 receptor inhibition prevents against lipopolysaccharide -induced osteoporosis by inhibiting osteoclast formation. Biomed Pharmacother. 2019;115: 108916.PubMedCrossRef
193.
Zaiss, M. et al. Binding immunoglobulin protein (BIP) inhibits TNF‐α–induced osteoclast differentiation and systemic bone loss in an erosive arthritis model. ACR Open Rheumatol. 1, (2019).
194.
Irvine K, et al. A CSF-1 receptor kinase inhibitor targets effector functions and inhibits pro-inflammatory cytokine production from murine macrophage populations. FASEB J. 2006;20:1921–3.PubMedCrossRef
195.
Paniagua RT, et al. C-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis. Arthritis Res Ther. 2010;12:R32.PubMedPubMedCentralCrossRef
196.
Murray LJ, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis. 2003;20:757–66.PubMedCrossRef
197.
Ramesh A, Brouillard A, Kumar S, Nandi D, Kulkarni A. Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy. Biomaterials. 2020;227: 119559.PubMedCrossRef
198.
Rattanaburee T, Tipmanee V, Tedasen A, Thongpanchang T, Graidist P. Inhibition of CSF1R and AKT by (±)-kusunokinin hinders breast cancer cell proliferation. Biomed Pharmacother. 2020;129: 110361.PubMedCrossRef
199.
200.
Rattanaburee T, Tipmanee V, Tedasen A, Thongpanchang T, Graidist P. Inhibition of CSF1R and AKT by (±)-kusunokinin hinders breast cancer cell proliferation. Biomed Pharmacother. 2020;129: 110361.PubMedCrossRef
201.
Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf. 2013;36:491–503.PubMedCrossRef
202.
Kumari A, Silakari O, Singh RK. Recent advances in colony stimulating factor-1 receptor/c-FMS as an emerging target for various therapeutic implications. Biomed Pharmacother. 2018;103:662–79.PubMedCrossRef
203.
Wiktor-Jedrzejczak W, et al. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci U S A. 1990;87:4828–32.PubMedPubMedCentralCrossRef
204.
Gerngross L, Lehmicke G, Belkadi A, Fischer T. Role for cFMS in maintaining alternative macrophage polarization in SIV infection: implications for HIV neuropathogenesis. J Neuroinflammation. 2015;12:1–15.CrossRef
205.
Clanchy FIL, Hamilton JA. HUVEC co-culture and haematopoietic growth factors modulate human proliferative monocyte activity. Cytokine. 2012;59:31–4.PubMedCrossRef
206.
Ohno H, et al. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther. 2006;5:2634–43.PubMedCrossRef
207.
Saleh, R. et al. CSF-1 in inflammatory and arthritic pain development. J. Immunol. 201, 2042 LP – 2053 (2018).
208.
Lim AKH, et al. Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice. Diabetologia. 2009;52:1669–79.PubMedCrossRef
209.
Tian L, et al. Macrophage-based combination therapies as a new strategy for cancer immunotherapy. Kidney Dis. 2022;8:26–43.CrossRef
210.
Edwards 5th, D. K. et al. CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells. Blood. 2019;133, 588–599.
211.
Edwards V, D. K. et al. CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells. Blood, 2019; 133, 588–599.
212.
213.
Zhu Y, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74:5057–69.PubMedPubMedCentralCrossRef
214.
Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8:86.PubMedPubMedCentralCrossRef
215.
Metadaten
Titel
Macrophage subsets and their role: co-relation with colony-stimulating factor-1 receptor and clinical relevance
verfasst von
Shivani Yadav
Astik Priya
Diksha R. Borade
Reena Agrawal-Rajput
Publikationsdatum
21.10.2022
Verlag
Springer US
Erschienen in
Immunologic Research / Ausgabe 2/2023
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-022-09330-8

Weitere Artikel der Ausgabe 2/2023

Immunologic Research 2/2023 Zur Ausgabe

Correction

Correction to: H19 is involved in the regulation of inflammatory responses in acute gouty arthritis by targeting miR-22-3p

Retraction Note

Retraction Note: Neuroprotective effects of G-CSF administration in microglia-mediated reactive T cell activation in vitro

Review

miRNAs as the important regulators of myasthenia gravis: involvement of major cytokines and immune cells

Original Article

Autophagic reprogramming of bone marrow–derived macrophages

Original Article

Immunotherapeutic effects of intratumorally injected Zymosan-Adenovirus conjugates encoding constant active IRF3 in a melanoma mouse model

Correction

Correction to: Matrine suppresses expression of adhesion molecules and chemokines as a mechanism underlying its therapeutic effect in CNS autoimmunity

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise